Crossref
26-A-16842-ACC REAL WORLD IMPACT OF TIRZEPATIDE ON CLASS III OBESE PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION
JACC · 2026-04 · 87 (13) · A64
DOI: 10.1016/j.jacc.2026.02.160 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC, 2026-04. Verfasst von Justin Haloot und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Haloot, J., Truly, T., Sori, E., & Giorgberidze, I. (2026). 26-A-16842-ACC REAL WORLD IMPACT OF TIRZEPATIDE ON CLASS III OBESE PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION. JACC, 87(13), A64. https://doi.org/10.1016/j.jacc.2026.02.160
Vancouver
Haloot J, Truly T, Sori E, Giorgberidze I. 26-A-16842-ACC REAL WORLD IMPACT OF TIRZEPATIDE ON CLASS III OBESE PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION. JACC. 2026;87(13):A64. doi:10.1016/j.jacc.2026.02.160
BibTeX
@article{Haloot2026,
author = {Haloot, Justin and Truly, Tate and Sori, Ermias and Giorgberidze, Irakli},
title = {26-A-16842-ACC REAL WORLD IMPACT OF TIRZEPATIDE ON CLASS III OBESE PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION},
journal = {JACC},
year = {2026},
volume = {87},
number = {13},
pages = {A64},
doi = {10.1016/j.jacc.2026.02.160}
}
EUVIMED